Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (925)	6/10/2000 12:27:00 AM
From: Julian	Respond to of 1321

QLT presents June 12 at 4:00pm gs.com

To: Ian@SI who wrote (925)	6/16/2000 9:53:00 PM
From: Julian	Respond to of 1321

Zeiss Reports Sales Over 500 Visulas(TM) 690s PDT Lasers Worldwide DUBLIN, Calif., Jun 16, 2000 /PRNewswire via COMTEX/ -- Zeiss Humphrey Systems announced today that worldwide demand for the VISULAS 690s PDT Laser has surpassed expectations. Over 500 VISULAS 690s lasers have been sold worldwide since the release of the product. The U.S. Food and Drug Administration (FDA) approved the use of Zeiss Visulas 690s Laser for the activation of Visudyne(TM) (verteporfin for injection) therapy to treat wet age-related macular degeneration (AMD), the leading cause of blindness among people over the age of 50. The Zeiss Visulas(TM) 690s Laser activates Visudyne(TM) for the treatment of wet AMD, and was the ONLY commercially produced laser in Visudyne Phase III FDA clinical trials. +I am delighted to see retina specialists around the world have made our PDT laser the laser of choice when treating this devastating degenerative disease. We were able to enhance the lives of many AMD patients throughout the Phase III clinical trials and now have over two years of efficacy and safety information,+ noted Dr. Victor Miranda, PDT Marketing Manager of Zeiss Humphrey Systems